Ravulizumab exposure and free C5 suppression
A reduced PK/PD model linking ravulizumab exposure to concentration-dependent suppression and recovery of free complement C5.
- Therapeutic
- Ravulizumab
- Target
- Complement C5
- Disease
- Neuromyelitis optica spectrum disorder
Biological model
A reduced PK/PD model linking ravulizumab exposure to concentration-dependent suppression and recovery of free complement C5.
Intervention
Ravulizumab
Biological focus
Complement C5
Context
Neuromyelitis optica spectrum disorder
Model details
A reduced PK/PD model linking ravulizumab exposure to concentration-dependent suppression and recovery of free complement C5.
Modeled states
- auc ug day mlug*day/mL
Modeled dynamic state for auc ug day ml.
- central mgmg
Modeled dynamic state for central mg.
- free c5 ug mlug/mL
Modeled dynamic state for free c5 ug ml.
Key readouts
- Central ravulizumab amountmg
Model-derived readout for central ravulizumab amount.
- Free complement C5ug/mL
Model-derived readout for free complement c5.
- Cumulative ravulizumab exposureug*day/mL
Model-derived readout for cumulative ravulizumab exposure.
- out ada baseline positive countunknown
Model-derived readout for out ada baseline positive count.
- out ada baseline positive pctunknown
Model-derived readout for out ada baseline positive pct.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Body weight 40 to <60 kg week-50 PK/free-C5
How do weight-based ravulizumab regimens maintain exposure and suppression of free C5? Explore this intervention regimen through Central ravulizumab amount, Free complement C5, Cumulative ravulizumab exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do weight-based ravulizumab regimens maintain exposure and suppression of free C5?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do weight-based ravulizumab regimens maintain exposure and suppression of free C5?
apparent volume l
Model parameter controlling apparent volume l.
Exploratory range around the default value.
5 evenly spaced values in L. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderFrontiers in Neurology
